Ignite Creation Date:
2025-12-24 @ 4:16 PM
Ignite Modification Date:
2026-01-01 @ 10:31 PM
Study NCT ID:
NCT01949766
Status:
NO_LONGER_AVAILABLE
Last Update Posted:
2013-09-24
First Post:
2013-09-20
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Transition From Buphenyl to RAVICTI for the Therapy of Byler Disease
Sponsor:
University of Pittsburgh
Organization:
Study Overview
Official Title:
Transition From Buphenyl to RAVICTI for the Therapy of Byler Disease
Status:
NO_LONGER_AVAILABLE
Status Verified Date:
2013-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a single patient compassionate use protocol to determine whether RAVICTI will improve bile flow in a subject who previously tolerated therapy with Buphenyl.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?: